188 related articles for article (PubMed ID: 37360908)
1. Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma.
Zhu C; Ma J; Zhu K; Yu L; Zheng B; Rao D; Zhang S; Dong L; Gao Q; Zhang X; Xie D
JHEP Rep; 2023 Aug; 5(8):100762. PubMed ID: 37360908
[TBL] [Abstract][Full Text] [Related]
2. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
Ding GY; Ma JQ; Yun JP; Chen X; Ling Y; Zhang S; Shi JY; Chang YQ; Ji Y; Wang XY; Tan WM; Yuan KF; Yan B; Zhang XM; Liang F; Zhou J; Fan J; Zeng Y; Cai MY; Gao Q
J Hepatol; 2022 Mar; 76(3):608-618. PubMed ID: 34793865
[TBL] [Abstract][Full Text] [Related]
3. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
[TBL] [Abstract][Full Text] [Related]
4. Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.
Lin Y; Peng L; Dong L; Liu D; Ma J; Lin J; Chen X; Lin P; Song G; Zhang M; Liu Y; Rao J; Wei C; Lu Y; Zhang S; Ding G; Peng Z; Lu H; Wang X; Zhou J; Fan J; Wu K; Gao Q
Cancer Discov; 2022 Oct; 12(10):2350-2371. PubMed ID: 35853232
[TBL] [Abstract][Full Text] [Related]
5. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
6. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
[TBL] [Abstract][Full Text] [Related]
7. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
8. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M
J Hepatol; 2024 Mar; ():. PubMed ID: 38508240
[TBL] [Abstract][Full Text] [Related]
9. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.
Jarman EJ; Horcas-Lopez M; Waddell SH; MacMaster S; Gournopanos K; Soong DYH; Musialik KI; Tsokkou P; Ng ME; Cambridge WA; Wilson DH; Kagey MH; Newman W; Pollard JW; Boulter L
Liver Int; 2023 Jan; 43(1):208-220. PubMed ID: 35924447
[TBL] [Abstract][Full Text] [Related]
10. Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents.
Nishida N; Kudo M
Liver Cancer; 2024 Apr; 13(2):136-149. PubMed ID: 38751556
[TBL] [Abstract][Full Text] [Related]
11. Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.
Chung T; Park YN
Front Med (Lausanne); 2022; 9():857140. PubMed ID: 35433771
[TBL] [Abstract][Full Text] [Related]
12. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
[TBL] [Abstract][Full Text] [Related]
13. CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype.
Mancarella S; Serino G; Gigante I; Cigliano A; Ribback S; Sanese P; Grossi V; Simone C; Armentano R; Evert M; Calvisi DF; Giannelli G
J Exp Clin Cancer Res; 2022 Feb; 41(1):65. PubMed ID: 35172861
[TBL] [Abstract][Full Text] [Related]
14. Exploring the role of tumor stemness and the potential of stemness-related risk model in the prognosis of intrahepatic cholangiocarcinoma.
Yue Y; Tao J; An D; Shi L
Front Genet; 2022; 13():1089405. PubMed ID: 36712866
[No Abstract] [Full Text] [Related]
15. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice.
Wabitsch S; Tandon M; Ruf B; Zhang Q; McCallen JD; McVey JC; Ma C; Green BL; Diggs LP; Heinrich B; Greten TF
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1166-1178. PubMed ID: 34033968
[TBL] [Abstract][Full Text] [Related]
17. Stage-specificity of STING activation in intrahepatic cholangiocarcinoma determines the efficacy of its agonism.
Luo S; Li S; Liu C; Yu D; Sun L; Zhang S; Zhao N; Zhang M; Nie J; Zhao Y; Li C; Zhang Y; Zhang Q; Meng H; Li X; Shi J; Zheng T
Cancer Lett; 2024 May; 594():216992. PubMed ID: 38797231
[TBL] [Abstract][Full Text] [Related]
18. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.
Lin J; Dai Y; Sang C; Song G; Xiang B; Zhang M; Dong L; Xia X; Ma J; Shen X; Ji S; Zhang S; Wang M; Fang H; Zhang X; Wang X; Zhang B; Zhou J; Fan J; Zhou H; Gao D; Gao Q
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863823
[TBL] [Abstract][Full Text] [Related]
19. Dense GM-CSFR
Saranaruk P; Waraasawapati S; Chamgramol Y; Sawanyawisuth K; Paungpan N; Somphud N; Wongkham C; Okada S; Wongkham S; Vaeteewoottacharn K
PeerJ; 2023; 11():e14883. PubMed ID: 36883059
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
